- Home
- KMI vs TAK Comparison
KMI vs TAK Comparison
Compare KMI & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KMI
- TAK
- Stock Information
- Founded
- KMI 1936
- TAK 1781
- Country
- KMI United States
- TAK Japan
- Employees
- KMI N/A
- TAK N/A
- Industry
- KMI Natural Gas Distribution
- TAK Biotechnology: Pharmaceutical Preparations
- Sector
- KMI Utilities
- TAK Health Care
- Exchange
- KMI Nasdaq
- TAK Nasdaq
- Market Cap
- KMI 59.2B
- TAK 47.3B
- IPO Year
- KMI 2011
- TAK N/A
- Fundamental
- Price
- KMI $27.36
- TAK $15.11
- Analyst Decision
- KMI Buy
- TAK
- Analyst Count
- KMI 14
- TAK 0
- Target Price
- KMI $29.86
- TAK N/A
- AVG Volume (30 Days)
- KMI 11.8M
- TAK 3.1M
- Earning Date
- KMI 10-15-2025
- TAK 10-30-2025
- Dividend Yield
- KMI 4.27%
- TAK 3.60%
- EPS Growth
- KMI 11.35
- TAK N/A
- EPS
- KMI 1.22
- TAK 0.59
- Revenue
- KMI $15,969,000,000.00
- TAK $31,053,301,865.00
- Revenue This Year
- KMI $11.25
- TAK $0.40
- Revenue Next Year
- KMI $5.46
- TAK $0.83
- P/E Ratio
- KMI $22.48
- TAK $25.50
- Revenue Growth
- KMI 3.97
- TAK 1.52
- 52 Week Low
- KMI $21.30
- TAK $12.80
- 52 Week High
- KMI $31.48
- TAK $15.69
- Technical
- Relative Strength Index (RSI)
- KMI 52.06
- TAK 51.77
- Support Level
- KMI N/A
- TAK $14.87
- Resistance Level
- KMI $27.81
- TAK $15.38
- Average True Range (ATR)
- KMI 0.40
- TAK 0.17
- MACD
- KMI -0.88
- TAK -0.03
- Stochastic Oscillator
- KMI 98.38
- TAK 35.71
About KMI Kinder Morgan Inc.
Kinder Morgan is one of the largest midstream energy firms in the US, with an interest in or an operator on more than 80,000 miles of gas, refined products, and carbon dioxide pipelines. The company also owns one of the largest portfolios of gas and refined products storage and terminals. Most of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.